Analysts Expect Immune Design Corp (IMDZ) Will Post Earnings of -$0.62 Per Share

Brokerages expect Immune Design Corp (NASDAQ:IMDZ) to post earnings of ($0.62) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Immune Design Corp’s earnings. The lowest EPS estimate is ($0.70) and the highest is ($0.55). Immune Design Corp reported earnings per share of ($0.61) during the same quarter last year, which suggests a negative year-over-year growth rate of 1.6%. The firm is expected to report its next earnings report on Tuesday, May 9th.

On average, analysts expect that Immune Design Corp will report full-year earnings of ($2.39) per share for the current year, with EPS estimates ranging from ($2.55) to ($2.25). For the next year, analysts expect that the business will report earnings of ($2.31) per share, with EPS estimates ranging from ($3.01) to ($1.59). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Immune Design Corp.

Immune Design Corp (NASDAQ:IMDZ) last posted its earnings results on Tuesday, March 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.57). Immune Design Corp had a negative net margin of 415.05% and a negative return on equity of 50.92%.

IMDZ has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Immune Design Corp from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Jefferies Group LLC reiterated a “buy” rating and set a $15.00 target price on shares of Immune Design Corp in a research report on Tuesday, February 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $16.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMDZ. Versant Venture Management LLC bought a new position in Immune Design Corp during the third quarter worth about $16,738,000. JPMorgan Chase & Co. increased its position in Immune Design Corp by 10.2% in the third quarter. JPMorgan Chase & Co. now owns 271,802 shares of the company’s stock worth $2,060,000 after buying an additional 25,127 shares during the last quarter. Monashee Investment Management LLC bought a new position in Immune Design Corp during the third quarter worth about $379,000. Sphera Funds Management LTD. increased its position in Immune Design Corp by 32.7% in the third quarter. Sphera Funds Management LTD. now owns 203,000 shares of the company’s stock worth $1,539,000 after buying an additional 50,000 shares during the last quarter. Finally, BVF Inc. IL bought a new position in Immune Design Corp during the third quarter worth about $9,096,000. Institutional investors own 53.07% of the company’s stock.

Immune Design Corp (NASDAQ:IMDZ) traded down 2.54% during mid-day trading on Thursday, hitting $5.75. 77,911 shares of the stock were exchanged. The company’s market capitalization is $146.27 million. Immune Design Corp has a 52 week low of $4.50 and a 52 week high of $16.94. The stock’s 50-day moving average is $6.17 and its 200 day moving average is $6.47.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Immune Design Corp (IMDZ) Will Post Earnings of -$0.62 Per Share” was first published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sleekmoney.com/analysts-expect-immune-design-corp-imdz-will-post-earnings-of-0-62-per-share/1739693.html.

About Immune Design Corp

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Get a free copy of the Zacks research report on Immune Design Corp (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/analysts-expect-immune-design-corp-imdz-will-post-earnings-of-0-62-per-share/1739693.html

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *